FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3030432790> ?p ?o ?g. }

• W3030432790 endingPage "4523" @default.
• W3030432790 startingPage "4523" @default.
• W3030432790 abstract "4523 Background: First-line treatment with pembro or pembro + chemo vs chemo alone was evaluated in patients with PD-L1 combined positive score (CPS) ≥1, HER2-negative advanced gastric cancer in the randomized, active-controlled, phase 3 KEYNOTE-062 study (NCT02494583). We present results from the Asian subpopulation receiving pembro monotherapy or chemo. Methods: Eligible patients were randomly assigned 1:1:1 to pembro 200 mg, pembro + chemo (cisplatin + 5-FU or capecitabine), or placebo + chemo every 3 weeks for ≤35 cycles (~2 years). Randomization was stratified by region, disease status, and fluoropyrimidine treatment. Primary end points for this analysis were overall survival (OS) in patients with CPS ≥1 and patients with CPS ≥10; progression-free survival (PFS) and objective response rate (ORR) were exploratory end points. Data cutoff was March 26, 2019. Results: Globally, 256 patients received pembro monotherapy and 250 received chemo. Pembro was noninferior to chemo for OS in CPS ≥1 per prespecified margins (median OS, 10.6 vs 11.1 months, respectively; HR [99.2% CI], 0.91 [0.69-1.18]). In the Asian population 62 patients received pembro and 61 received chemo; 26 and 22 had CPS ≥10 (Table). Compared with the global population, Asian patients had a higher proportion of ECOG performance status 0, more diagnoses of stomach cancer, and a greater proportion with 0-2 metastatic sites. Median OS was longer with pembro than chemo using both CPS cutoffs (HR [95% CI]: CPS ≥1, 0.54 [0.35-0.82]; CPS ≥10, 0.43 [0.21-0.89]); 12- and 24-month OS rates were higher for pembro using both CPS cutoffs (12-month OS: CPS ≥1, 69% vs 54%; CPS ≥10, 81% vs 68%; 24-month OS: CPS ≥1, 45% vs 23%; CPS ≥10, 54% vs 27%). The HR (95% CI) for PFS was 1.11 (0.76-1.64) for CPS ≥1 and 0.71 (0.36-1.39) for CPS ≥10. Conclusions: In Asian patients with advanced gastric cancer, OS favored pembro in patients with CPS ≥1 and CPS ≥10. Clinical trial information: NCT02494583 . [Table: see text]" @default.
• W3030432790 created "2020-06-05" @default.
• W3030432790 creator A5002562596 @default.
• W3030432790 creator A5015799240 @default.
• W3030432790 creator A5016038702 @default.
• W3030432790 creator A5019406140 @default.
• W3030432790 creator A5023165272 @default.
• W3030432790 creator A5026090288 @default.
• W3030432790 creator A5039574304 @default.
• W3030432790 creator A5040552693 @default.
• W3030432790 creator A5045819149 @default.
• W3030432790 creator A5053209984 @default.
• W3030432790 creator A5057554500 @default.
• W3030432790 creator A5070257043 @default.
• W3030432790 creator A5077255843 @default.
• W3030432790 creator A5083227748 @default.
• W3030432790 creator A5089294515 @default.
• W3030432790 creator A5090832721 @default.
• W3030432790 date "2020-05-20" @default.
• W3030432790 modified "2023-10-18" @default.
• W3030432790 title "Pembrolizumab (pembro) versus standard of care chemotherapy (chemo) in patients with advanced gastric or gastroesophageal junction adenocarcinoma: Asian subgroup analysis of KEYNOTE-062." @default.
• W3030432790 doi "https://doi.org/10.1200/jco.2020.38.15_suppl.4523" @default.
• W3030432790 hasPublicationYear "2020" @default.
• W3030432790 type Work @default.
• W3030432790 sameAs 3030432790 @default.
• W3030432790 citedByCount "9" @default.
• W3030432790 countsByYear W30304327902020 @default.
• W3030432790 countsByYear W30304327902021 @default.
• W3030432790 countsByYear W30304327902022 @default.
• W3030432790 countsByYear W30304327902023 @default.
• W3030432790 crossrefType "journal-article" @default.
• W3030432790 hasAuthorship W3030432790A5002562596 @default.
• W3030432790 hasAuthorship W3030432790A5015799240 @default.
• W3030432790 hasAuthorship W3030432790A5016038702 @default.
• W3030432790 hasAuthorship W3030432790A5019406140 @default.
• W3030432790 hasAuthorship W3030432790A5023165272 @default.
• W3030432790 hasAuthorship W3030432790A5026090288 @default.
• W3030432790 hasAuthorship W3030432790A5039574304 @default.
• W3030432790 hasAuthorship W3030432790A5040552693 @default.
• W3030432790 hasAuthorship W3030432790A5045819149 @default.
• W3030432790 hasAuthorship W3030432790A5053209984 @default.
• W3030432790 hasAuthorship W3030432790A5057554500 @default.
• W3030432790 hasAuthorship W3030432790A5070257043 @default.
• W3030432790 hasAuthorship W3030432790A5077255843 @default.
• W3030432790 hasAuthorship W3030432790A5083227748 @default.
• W3030432790 hasAuthorship W3030432790A5089294515 @default.
• W3030432790 hasAuthorship W3030432790A5090832721 @default.
• W3030432790 hasConcept C121608353 @default.
• W3030432790 hasConcept C126322002 @default.
• W3030432790 hasConcept C143998085 @default.
• W3030432790 hasConcept C2777909004 @default.
• W3030432790 hasConcept C2908647359 @default.
• W3030432790 hasConcept C526805850 @default.
• W3030432790 hasConcept C71924100 @default.
• W3030432790 hasConcept C99454951 @default.
• W3030432790 hasConceptScore W3030432790C121608353 @default.
• W3030432790 hasConceptScore W3030432790C126322002 @default.
• W3030432790 hasConceptScore W3030432790C143998085 @default.
• W3030432790 hasConceptScore W3030432790C2777909004 @default.
• W3030432790 hasConceptScore W3030432790C2908647359 @default.
• W3030432790 hasConceptScore W3030432790C526805850 @default.
• W3030432790 hasConceptScore W3030432790C71924100 @default.
• W3030432790 hasConceptScore W3030432790C99454951 @default.
• W3030432790 hasIssue "15_suppl" @default.
• W3030432790 hasLocation W30304327901 @default.
• W3030432790 hasOpenAccess W3030432790 @default.
• W3030432790 hasPrimaryLocation W30304327901 @default.
• W3030432790 hasRelatedWork W192535437 @default.
• W3030432790 hasRelatedWork W1971434702 @default.
• W3030432790 hasRelatedWork W1973988934 @default.
• W3030432790 hasRelatedWork W2127296490 @default.
• W3030432790 hasRelatedWork W3209191848 @default.
• W3030432790 hasRelatedWork W4224439900 @default.
• W3030432790 hasRelatedWork W4252041827 @default.
• W3030432790 hasRelatedWork W4252495345 @default.
• W3030432790 hasRelatedWork W2911150495 @default.
• W3030432790 hasRelatedWork W3109960249 @default.
• W3030432790 hasVolume "38" @default.
• W3030432790 isParatext "false" @default.
• W3030432790 isRetracted "false" @default.
• W3030432790 magId "3030432790" @default.
• W3030432790 workType "article" @default.